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ABSTRACT 
SOROKA, STANLEY Point Mutations of the Putative Follitropin Receptor 
 Caveolin Interaction Motif Do Not Disrupt Receptor Function. 
 Biochemistry Department, June 2016 
 
ADVISOR: Brian D. Cohen 
 
Human follicle stimulating hormone (hFSH) is a hormone found in humans that is 
synthesized and secreted by the anterior pituitary and targets the ovaries and testes.  This 
specificity of targeting is accomplished by the interaction of hFSH with its receptor 
(hFSHR) on target cells. hFSHR is a G protein-coupled receptor that localizes to domains 
in the cell membrane known as lipid rafts.  The mechanism of translocation of the hFSHR 
into lipid rafts is unknown.   Our hypothesis is that translocation occurs through 
interaction of hFSHR with the protein caveolin via a specific sequence in the hFSHR; a 
putative caveolin interaction motif (CIM).  The canonical caveolin interaction motif, 
FXFXXXXFXXF, where F is any aromatic amino acid such as phenylalanine (F), 
tyrosine (Y) or tryptophan (W) is found in the fourth transmembrane domain of hFSHR 
in amino acids 479-489 (FAFAAALFPIF). Here, the 4 critical phenylalanine residues 
match the motif. The goal of the current research has been to produce stable cell lines 
expressing isoforms of hFSHR with one of each of the four phenylalanines mutated to 
leucine. The mutant receptors were expressed in the cells and qualitatively demonstrated 
normal signaling when stimulated by hFSH. Future studies will focus on analyzing 
quantitative measurement of signaling and the location of the mutant receptor on the cell 
surface.  Understanding the caveolin interaction motif of hFSHR could give us better 
understanding of the mechanism of hFSHR localization to lipid rafts and may give 
insight into a novel way to regulate FSH signaling and function.
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Introduction 
Plasma Membrane 
Every cell is constructed with a plasma membrane separating the interior of the 
cell from its surroundings. As shown in Figure 1, this membrane is a combination of 
lipids, proteins, and in the case of eukaryotes, sterols. 1 The most common lipids in the 
membrane are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and 
sphingomyelin. 2 These lipids all have 
cylindrical Van der Waals envelopes (Figure 
2); when the lipids are in aqueous 
environments, the hydrophobic tails are pushed 
together forming a bilayer.  This is known as 
the hydrophobic effect. 3 Because the middle of 
the plasma membrane is hydrophobic, the cell is impermeable to water-soluble 
molecules. 
Figure	1.	Singer-Nicolson	Augmented	model	of	the	plasma	membrane.	 25	
Figure	2.	Cylindrical,	bilayer	lipid	and	the	bilayer	it	
forms	in	aqueous	solutions.	. 26 
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Figure	3.	The	activation	of	adenylyl	cyclase	as	a	result	
of	ligand	binding	to	a	GPCR.		Binding	activates	the	
GPCR	which	then	promotes	the	exchange	of	GDP	for	
GTP	in	the	alpha	subunit.	The	alpha	unit	can	then	
activate	effector	proteins,	such	as	adenylyl	cyclase. 
Although not all of the lipids have hydrocarbon tails with double bonds, when 
double bonds are present, they are usually cis, introducing kinks into the tails. 2 This 
makes them difficult to pack together and for this reason, the tails move freely within the 
membrane; there is also uncatalyzed lateral diffusion of the lipids themselves. 2 In animal 
cells, cholesterol is present in the membrane to increase or decrease fluidity, as 
necessary; it inserts itself into the bilayer, between lipids, with its polar hydroxyl group. 2 
The presence of cholesterol in between the lipids keeps the fatty acid tails from coming 
together and freezing at low temperatures. At high temperatures, cholesterol does the 
opposite. Its presence in between lipids interferes with the rotation of the fatty acid tails, 
limiting their movement.  2 
G-Protein Coupled Receptors 
Within the membrane are many 
different families of receptors.  One of the 
largest superfamilies of membrane-bound 
receptors is the g protein coupled receptors 
(GPCRs). 4 GPCRs make up about 3% of all 
human genes representing between 750 and 
800 different GPCRs.  Individual cells 
express less than 100 different GPCRs, a 
number of different G protein subunits, and 
various G protein-linked effectors. 4 
Transmission of a signal by GPCRs requires 
physical interaction between the receptor, a guanosine nucleotide-binding protein (G 
protein) subunit, and an effector molecule. 4 Signal transduction occurs when the receptor 
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is activated by its ligand.  This interaction causes a conformational change in the receptor 
that allows it to function as a guanine exchange factor (GEF). 5 As a GEF, the receptor 
acts on its coupled, inactive G protein on the cytosolic side of the membrane.  It 
facilitates the release of bound GDP from the G protein and binding of free GTP from the 
cytosol, activating the G protein.  Once activated, the G protein dissociates from the 
receptor and binds to a nearby effector protein, usually an enzyme.  This binding alters 
the activity of the enzyme. 5   
These components required for signaling, however, are expressed on the cell 
surface at relatively low levels, less than 10,000/cell. 6 At these concentrations, a uniform 
distribution of the components would be extremely unlikely to allow for interaction and 
sufficient signal transduction, but somehow signal transduction still occurs rapidly and 
efficiently.  One mechanism that may explain how signal transduction is facilitated is that 
cells concentrate signaling molecules within membrane microdomains.  4 
Lipid Rafts 
The multitude of saturated hydrocarbon chains in cell membrane sphingolipids 
allows for cholesterol to be tightly intercalated. 7 This leads to membrane rigidity and the 
formation of microdomains known as lipid rafts. 8 The tight packing of the cholesterol 
and sphingolipids within the membrane causes the high melting temperature of these 
microdomains. 9 Rafts can be characterized as caveolar or non-caveolar; caveolar lipid 
rafts are flask shaped invaginations in the membrane and non-caveolar rafts are planar 
microdomains. 10 
Studies have concluded that lipid rafts provide both a spatial and temporal 
meeting point for signaling molecules. It is believed that lipid rafts can coordinate 
specific signaling events by influencing the inclusion or exclusion of receptors and their 
	 4	
Figure	4.	Linear	and	Caveolar	Lipid	Rafts 27 
associated effector molecules. 10 Lipid rafts also influence g protein-coupled-receptor 
signaling (GPCR). 10 Lipid rafts can localize or move any of the components required for 
transducing the signal as a way of modifying receptor signaling.  Studies show, however, 
that GPCR components are more likely to be confined within lipid rafts. 4 This may 
explain how stable complexes are able to be formed between the separate components of 
the GPCR pathway. Disrupting lipid rafts has resulted in reductions in G protein coupling 
and binding of agonists to GPCRs, providing support to the theory that lipid rafts 
facilitate coupling of the G protein and receptor. 4 Many of these couplings have been 
found to occur in the previously mentioned lipid raft subsets called caveolae.  
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Figure	5.	Schematic	representation	of	the	lipid	and	protein	organization	of	caveolae	4	
Caveolae 
Caveolae are thought to be a subset of lipid rafts that comprise about 1% of the 
plasma membrane surface area of the cells that express them.  They are approximately 
50-100 nm in diameter and were first identified during the 1950s by their “flask-shape” 
on the cell surface.  In addition to the usual characteristics of lipid rafts, caveolae 
characteristically contain caveolin proteins localized on the inner leaflet of the membrane 
bilayer. 11 Caveolae are present in cells from most tissues but are particularly abundant in 
adipocytes, endothelial cells, type I pneumocytes, fibroblasts, and smooth and striated 
muscle cells. Alternatively, cells such as neurons and lymphocytes normally lack 
caveolae. 12 Within caveolin expressing cells, caveolae function in transcytosis, 
endocytosis, exocytosis, cholesterol homeostasis, and receptor and ion-channel 
expression, activation, and desensitization. 12 
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Caveolin 
Caveolin proteins are located solely on the cytoplasmic side of the plasma membrane 
and are considered the molecular markers for caveolae.  Three different isoforms of the 
protein exist: caveolin-1, caveolin-2, and caveolin-3.  Caveolae generally form in cells 
expressing caveolin-1, the predominant isoform, or caveolin-3, the striated muscle-
specific isoform. 13  Caveolin-2 is found in hetero-oligomers with caveolin-1 and 
caveolin-3, but it is not clear if caveolin-2 can induce caveolae biosynthesis on its own. 14  
The three isoforms have a similar structure consisting of a hairpin loop with both the C 
and N termini on the cytoplasmic side of the membrane. Knock out experiments 
performed in mice show that the isoforms have different patterns of regulation of 
enzymatic and functional activities. 12 
Within caveolae, caveolin has three major functions. First, it helps maintain the 
structural integrity of the caveolae. The curvature of the membrane creates physical stress 
on the membrane that caveolin helps to alleviate by “filling in” the stretched side of the 
membrane (Figure 4). 15 Secondly, caveolin acts as a scaffolding protein. In this role, 
caveolin recruits various molecules into the raft region. Lastly, caveolin acts as a protein 
chaperone and functions in cell membrane trafficking. 15 
Multiple domains have been identified within the structure of the caveolin monomer.  
The scaffolding domain that exists likely serves as an anchor for signaling components.  
Caveolin also contains and oligomerization domain.  This is the site of interaction where 
the high-weight oligomers seen in the caveolae are formed. 15  
Caveolin Interaction Motif 
Previous research has suggested that signaling proteins form direct protein-protein 
interactions with the scaffolding domain of caveolin (CSD) through a conserved peptide 
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sequence, the caveolin binding motif (CBM). 16 These consensus CBMs are hydrophobic 
and rich in aromatic residues. The typical sequences are 𝜙x𝜙xxxx𝜙 or 𝜙xxxx𝜙xx𝜙 or 
the combined sequence 𝜙x𝜙xxxx𝜙xx𝜙, where 𝜙 is a phenylalanine, tyrosine or 
tryptophan residue and x can be any amino acid (figure 6). 16 
Human Follicle Stimulating Hormone Receptor 
Follicle stimulating hormone, or follitropin, is a gonadotropin hormone secreted 
by the gonadotroph cells in the anterior pituitary. 17  In order to transduce a signal, FSH 
binds to its receptor, follicle stimulating hormone receptor (FSHR). FSHR is found on the 
surface of granulosa cells surrounding the immature follicle and oocyte in ovaries of 
women and on Sertoli cells in the testes of men. 17 Activation of FSHR by FSH directly 
promotes follicle maturation and estrogen production in females. 18 In males, FSH plays a 
role in establishing the population of Sertoli cells in the testicular seminiferous tubules 
and in the maintenance of sperm quality and number. 17  
 These aforementioned effects are the result of FSHR signaling through what is 
known as its canonical pathway.  When FSH binds to FSHR, the receptor transduces a 
signal through two different pathways, the canonical pathway and what is believed to be 
a desensitization and internalization pathway.   
Figure	6.	Caveolin	interaction	motif	and	conjugate	amino	acid	sequence	on	scaffolding	domain	of	caveolin	14 
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  FSHR is a GPCR (Figure 7).  The canonical pathway is dependent on FSHR’s 
action through it coupled G protein.  FSHR is primarily coupled to the G protein GSα. 19 
When activated, GSα alters the activity of the enzyme adenylyl cyclase, stimulating the 
production of cyclic AMP (cAMP). cAMP then activates Protein kinase A (PKA), which 
can activate the cAMP Response Element Binding Protein (CREB) pathway (Figure 3). 19  
This results in the previously discussed endocrine effects of FSH. 
Prolonged exposure to FSH, however, leads to desensitization.  This is decreased 
sensitivity and response to the hormone. 20 Desensitization is a result of receptor 
uncoupling, which decreases receptor function and occurs relatively rapidly after receptor 
stimulation. 20 FSHR is uncoupled from the GSα subunit due to phosphorylation of serine 
and threonine residues on the C terminal end of the receptor. This event results in the 
recruitment of inhibitor proteins known as arrestins. 21 Arrestins then recruit other 
Figure	7.	hFSHR	and	its	signaling	pathways 
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molecules that play a role in receptor down-regulation. 20 This is a slower desensitization 
process. The number of FSHRs on the cell surface decrease due to internalization through 
clathrin coated pit or caveolae endocytotic pathways. 22 Receptor numbers also begin to 
decrease as a result of decreased transcription, translation, or mRNA half-life. 
Human FSHR (hFSHR), like other GPCRs, has been shown to preferentially 
localize within microdomains in the cell membrane known as lipid rafts during signaling. 
23 More specifically, hFSHR has been observed to associate with caveolae (Cohen Lab).  
Research has shown that lipid rafts function as spatial and temporal meeting places for 
the molecules required to transduce a signal, like GPCRs. 24 
FSHR And Lipid Rafts 
The hFSHR sequence contains a canonical combined motif between amino acids 
479-489 (Figure 8) with each of the 𝜙’s of the CBD being a phenylalanine.10 In Figure 8, 
these residues are colored in with 479 as green and 489 as blue.  This provides a possible 
mechanism for the interaction of hFSHR with caveolin, although it does not help to 
understand the functional significance of either the sequence or the interaction. 
 
 
 
 
 To study the interactions of hFSHR with caveolin, mutated receptors have been 
synthesized.  Members of the Cohen lab individually mutated each of the phenylalanine 
residues of the CBD to a leucine residue using Splicing by Overlap Extension (Table 1).    
Caveolin Interaction Motif 
  Ф X Ф X X X X Ф X X Ф 
  F A F A A A L F P I F 
 479 481       486   489 
Figure	8.	hFSHR	with	combined	caveolin	interaction	motif	circled 17 
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The next step of this research is to transfect the mutated receptors into HEK293 cells.  
These transfected cells will be examined for proper expression of the receptor.  If the 
receptors are expressed properly, they will be tested for co-immunoprecipitation with 
caveolin and proper signal transduction. 
 Once the interaction between hFSHR and the lipid rafts is better understood, 
research can be focused on possible pharmaceutical interventions for infertility and novel 
birth control.  Specifically, research will be focused on synthesis of two different drugs, 
one that would enhance interaction between the receptor and caveolin and one that would 
interfere with the interactions. 
 
 
 
 
 
Table	1.	FSH	receptor	Mutagenesis	Oligonucleotides	for	Splicing	by	Overlap	Extension	
FSH Receptor Mutagenesis Oligonucleotides 
Normal 5’GTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCTGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAG 3’ 
Sequence 3’CAGTACCACTACCCGACCTAAAAACGAAAACGTCGACGGGAGAAAGGGTAGAAACCGTAGTCGTCGATGTACTTC 5’ 
F479L 
                                 5’GGCTGGATCCTTGCTTTTGCAGCTGCCCTC3’ C primer                                                BamHI 
3’CAGTACCACTACCCGACCTAGGAACGAAAACG5’           B primer 
  GCAAAAGCAAGGATCCAGCCCATCACCATGAC 
F481L 
                                      5’GATTTTTGCGCTAGCAGCTGCCCTCTTTCCC3’ C primer                                         NheI 
      3’CACTACCCGACCTAAAAACGCGATCGTCGACGG5’          B primer 
        GGCAGCTGCTAGCGCAAAAATCCAGCCCATCAC 
F486L 
EarI                                               5’GCAGCTGCTCTTCTTCCCATCTTTGGCATCAGC3’ C primer 
                 3’CTAAAAACGAAAACGTCGACGAGAAGAAGGGTAG5’             B primer 
                   GATGGGAAGAAGAGCAGCTGCAAAAGCAAAAATC 
F489L 
AvrII                                                    5’TTTCCCATCCTAGGCATCAGCAGCTACATGAAG3’C primer 
                                 3’CGACGGGAGAAAGGGTAGGATCCGTAGTCG5’            B primer 
                                   GCTGATGCCTAGGATGGGAAAGAGGGCAGC 
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Methods 
 
Cell Culture and DNA Transfection 
HEK293 cells were grown and maintained as monolayer cultures at 37°C in DMEM 
medium supplemented with 10% fetal bovine serum and penicillin:streptomycin. The 
cells were grown to 50-70% confluence before being transfected using X-tremeGENE 
HP DNA Transfection Reagent Roche) and the respective DNA. The HEK293 cells were 
transfected with wild-type or mutant FSHR plasmids for expression, localization, and 
signaling assays. 
 
SDS-PAGE and Western Blotting 
HEK293 cells were grown to a monolayer and transfected.  The cell’s proteins were then 
extracted by detergent lysis.  An Igepal/DOC lysis buffer (1% Igepal, 0.4% deoxycholate, 
10mM Tris-Cl pH 7, 6.6mM EDTA) was used with a 1X protease inhibitor cocktail. 
After BCA Assay analysis, the protein samples were linearized by treatment with SDS 
and separated on 10% poly-acrylamide gels by molecular mass.  The proteins were then 
transferred to a PVDF membrane and blocked with 5% milk in TBST.  The membranes 
were then probed with various antibodies.  Anti-hFSHR mAb 106.105 (105) was used to 
probe for hFSHR, P-p44/42 MAPK Rabbit Ab for phosphorylated p44, P-CREB Rabbit 
Ab for phosphorylated CREB, and p38 MAPK Rabbit Ab for total p38.  Finally, the 
membranes were probed with anti-mouse HRP antibody when probing with 105 and with 
anti-rabbit HRP when probing with phospho-p44, phospho-CREB, or p38. 
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Immunohistochemistry 
HEK293 cells were grown on glass cover slips and then transfected with wild-type or 
mutant FSHR plasmids. These cells were fixed using 4% paraformaldehyde in phosphate 
buffered saline (PBS). Primary antibody for the detection of FSHR was monoclonal 
antibody mAb106.105, the kind gift of Dr. James Dias (Wadsworth Center, Albany, NY). 
Goat anti-mouse with an Alexa-Red fluorophore was used as the secondary antibody. 
 
Stable Selection 
HEK293 cells were grown and transfected as described in Cell Culture and DNA 
Transfection.  The medium was then changed to one including G418 antibiotic in order to 
select for only the cells that were successfully transfected.  After several days in the G418 
medium, single colonies of the cells were transferred to their own wells of a 24-well dish 
for their amplification.  Once they reached confluence, they were moved to 12-well 
dishes, 6-well dishes, t-25 flasks, and finally t-75 flasks.   
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Results 
Single point mutations of the caveolin interaction motif do not disrupt receptor 
expression. 
SDS-PAGE and western blotting assays were performed to determine whether 
mutations of single aromatic residues of the caveolin interaction motif disrupted the 
expression of the mutant receptors by cells.  Results show that all four of the mutant 
receptors, and the wild type receptor, were successfully transfected into HEK293 cells 
and the cells were able to express them (Figure 9). 
 
 
 
 
 
 
 
 
 
 Expression of the mutant receptors was also analyzed by fluorescence 
microscopy.  Results support that the cells were successfully transfected with the wild 
type and mutant receptors and the cells express each of the receptors (Figure 10).   
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Figure	9.		Western	blot	of	lysates	transfected	with	wild-type	and	mutant	hFSHR	plasmids.		Probed	with	
anti-hFSHR	mAb	106.105	for	the	detection	of	FSHR. 
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HEK	293	 Wild	Type	
F479L	 F481L	
F486L	 F489L	
Figure	10.	Fluorescence	imaging	of	HEK293	cells	transfected	with	nothing,	wild	type	hFSHR,	and	the	three	hFSHR	single	mutant	
plasmids.		Cells	were	stained	with	Alexa	594	Goat	anti-Mouse	Ab	and	DAPI. 
	 15	
0	min	FSH 
5	min	FSH 
15	min	FSH 
105 Total	p38 pp44 		WT	479	481	486		489 			WT		479		481	486	489 	WT		479	481	486	489 
Single point mutations of the caveolin interaction motif do not disrupt receptor signaling 
SDS-PAGE and western blotting assays were performed to determine whether 
mutations of single aromatic residues of the caveolin interaction motif disrupted the 
ability of the mutant receptors to signal through the CREB and MAPK pathways when 
exposed to hormone for 0, 5, and 15 minutes before protein extraction.  Results show that 
all four of the mutant receptors, and the wild type receptor, successfully signaled through 
both pathways in response to hormone stimulation (Figures 11 and 12).  
 
 
 
 
 
 
 
 
 
 
 
p38 pCREB 
0	min	FSH 
5	min	FSH 
15	min	FSH 
		WT						479					481				486				489 		WT						479					481				486			489 
Figure	12.	Western	blot	analysis	of	protein	lysates	from	HEK293	cells	transfected	with	wild	type	and	single	mutant	
hFSHR	plasmids	probed	with	p38	MAPK	Rabbit	Ab	as	a	loading	control	and	P-CREB	Rabbit	Ab	to	determine	signaling	by	
the	canonical	pathway. 
Figure	11.	Western	blot	analysis	of	protein	lysates	from	HEK293	cells	transfected	with	wild	type	and	single	mutant	
hFSHR	plasmids	probed	with	anti-hFSHR	mAb	106.105	to	show	hFSH	expression,	p38	MAPK	Rabbit	Ab	as	a	loading	
control	and	P-p44/42	MAPK	Rabbit	Ab	to	determine	signaling	by	the	internalization	pathway. 
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Discussion 
 
 Four variant hFSHR plasmids with mutations in the caveolin interaction motif 
were previously created using splicing by overlap extension.  The phenylalanine residues 
of the caveolin interaction motif were mutated to leucine residues at amino acids 479, 
481, 486, and 489 of the hFSHR.  These plasmids were transfected into human 
embryonic kidney (HEK293) cells for various assays to determine the effect of the 
mutations on properties of the receptor. 
 Western blot analysis using anti-hFSHR mAb 106.105, an hFSHR-detecting 
antibody, demonstrated that the wild type and mutant receptors were present in the 
transfected cells.  Therefore, the single residue mutations did not affect the ability of the 
cells to transcribe and translate the plasmids into receptor proteins.   
 In order to determine if the mutant receptors could also be localized to the cell 
membrane by HEK293 cells, fluorescence microscopy assays using fluorescently tagged 
mAb 106.105 were performed.  Results show that the wild type and mutants receptors 
were indeed localized to the cell membrane in the HEK293 cells.  The transfected cells 
were not permeablized prior to incubation with mAb 106.105 and the fluorescently 
tagged secondary antibody so any fluorescence seen should correspond to antibody 
bound to receptors on the cell surface.   
 Receptor localization to the cell surface was also confirmed by western blot 
analysis using anti-Phospho p44 and anti-Phospho-CREB.  These antibodies detect 
phosphorylated p44 and CREB molecules.  p44 and CREB are phosphorylated 
downstream of two FSHR signaling pathways.  Levels of phosphorylated p44 and CREB 
were measured at 0, 5, and 15 minutes of exposure to FSH in order to determine if the 
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mutant receptors signaled like the wild type receptor.  Results show that the wild type and 
mutant receptors each signal in response to hormone stimulation. Variability in gel 
loading was observed (based on the total p38 staining in Figures 11 and 12) which 
prevents quantitative analysis of signaling activation by the mutant receptors.  However, 
any signaling is demonstrative of the presence of hFSHR CIM mutants on the cell 
membrane. 
Taken together, these results indicate that single mutations of a phenylalanine 
residue of the caveolin interaction motif do not disrupt completely disrupt expression, 
localization, and signaling of the hFSHR. The qualitative assays performed did not rule 
out the possibility that the mutations impacted the level of expression, localization to the 
cell surface, or signaling efficiency of the hFSHR mutants as compared to the wild type.   
Future experiments should include selection of stable cell lines expressing the 
mutant hFSHRs.  With stably selected cell lines, the quantitative expression assays can be 
performed and once expression is determined for the different mutants, the surface 
localization and signaling can be normalized to the number of receptors.  This will allow 
the researchers to compare the mutant and wild type receptors quantitatively on a per-
receptor basis and the effect of the mutations on receptor properties will be better 
understood.   
Once the effect of the single mutations is better understood, the focus can be 
turned to creating multiple mutants and performing different assays to see if additional 
mutations of the phenylalanine residues of the caveolin interaction motif will result in 
disruption of proper hFSHR function. 
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X-tremeGENE HP DNA Transfection Reagent
For transient and stable transfection of eukaryotic cells
y Version 08
Content version: January 2014
Cat. No. 06 365 752 001
Cat. No. 06 366 244 001
Cat. No. 06 366 236 001
Cat. No. 06 366 546 001
Trial-pack
0.4 ml
1 ml
5 × 1 ml
Store at –15 to –25°C
1. What this Product Does
Number of Tests
Using the standard procedure, 1 ml of X-tremeGENE HP DNA Trans-
fection Reagent can be used to perform up to 10,000 transfections in 
96-well plates.
Formulation
X-tremeGENE HP DNA Transfection Reagent is a proprietary blend of 
lipids and other components supplied in 80% ethanol, filtered through 
0.2 !m pore size membrane, and packaged in glass vials. It does not 
contain any ingredients of human or animal origin.
Storage and Stability
Store X-tremeGENE HP DNA Transfection Reagent at –15 to –25°C, 
with the lid tightly closed. The reagent is stable until the expiration 
date printed on the label when stored under these conditions.
 X-tremeGENE HP DNA Transfection Reagent remains fully func-
tional even after repeated opening of the vial (at least five times 
over a two-month period), as long as the vial is tightly recapped 
and stored at -15 to -25°C. 
 Note that the shipping temperature of this product is different 
from the storage temperature. These different temperatures will 
not affect product performance or product stability.
Special Handling
 After removing the amount required, tightly close the vial with the 
lid immediately after use.
 Always bring the vial to +15 to +25°C and mix X-tremeGENE HP 
DNA Transfection Reagent prior to removing the amount required 
vortexing for one second.
 Do not aliquot X-tremeGENE HP DNA Transfection Reagent; store 
in the original glass vials.
 Minimize the contact of undiluted X-tremeGENE HP DNA Trans-
fection Reagent with plastic surfaces.
 For use, the minimum amount of X-tremeGENE HP DNA Transfec-
tion Reagent: DNA complex is 100 µl. Complex formation at lower 
volumes can significantly decrease transfection efficiency.
 Do not use tubes or microplates made of polystyrene for 
X-tremeGENE HP Transfection Reagent : DNA complex prepara-
tion. When not able to avoid polystyrene materials, make certain to 
pipet the transfection reagent directly into the serum-free medium 
(e.g., Opti-Mem).
 Do not use siliconized pipette tips or tubes.
Additional Equipment and Reagents Required
Additional reagents and equipment required to perform transfection 
assays using X-tremeGENE HP DNA Transfection Reagent include:
➤ Standard Laboratory Equipment.
" Standard cell culture equipment (e.g., biohazard hoods, incuba-
tors)
" Standard pipettes and micropipettes
" Vortex mixer
➤ For Plasmid Preparation
" Purified plasmid stock (0.1 – 2.0 µg/µl) in sterile TE (10 mM Tris, 
1 mM EDTA, pH 8.0) buffer or sterile water
" Genopure Plasmid Midi Kit* or Genopure Plasmid Maxi Kit* to 
prepare plasmid
➤ For Verification of Vector Function
" Assay appropriately for transfected gene
" G-418 Solution* or Hygromycin B* (optional for stable transfec-
tion experiments)
➤ For Transfection-Complex Formation
" Opti-MEM I Reduced Serum Medium or serum-free medium
" Sterile polypropylene tubes or round-bottom 96-well plates
➤ Growing Cells
" Select subconfluent cultures in log phase for preparation of cell 
cultures
" Quantify cell number to reproducibly plate the same number of 
cells
Application
X-tremeGENE HP DNA Transfection Reagent is a high performance 
transfection reagent, free of animal-derived components. Benefits of 
X-tremeGENE HP DNA Transfection Reagent include:
• Designed to transfect a broad range of eukaryotic cells, including 
insect cells, many cell lines not transfected well by other reagents, 
and hard-to-transfect cell lines (e.g., HT-1080, K-562, HepG2). 
• Can be successfully used in a variety of applications, such as gene 
expression analysis and protein production using transiently trans-
fected cells, generation of stable cell lines, expression of shRNA for 
gene knockdown studies, drug discovery programs, and target 
evaluation. Samples and detailed transfection protocols are avail-
able at http://www.powerful-transfection.com.
• Produces minimal cytotoxicity or changes in morphology when ade-
quate numbers of cells are transfected, eliminating the requirement 
to change media after adding the transfection complex.
• Suitable for transient and stable transfection.
• Functions very well in the presence or absence of serum.
For life science research only.  
Not for use in diagnostic procedures.
0114.06479774001!
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2. How to Use this Product
2.1 Before You Begin
Required Amount of X-tremeGENE HP DNA Transfection 
Reagent
To optimize, first transfect a monolayer of cells that is 70 - 90% conflu-
ent, using 1:1, 2:1, 3:1 and 4:1 ratios of microliter (!l) X-tremeGENE HP 
DNA Transfection Reagent to microgram (!g) DNA. A ratio of 3:1 of 
microliter (!l) X-tremeGENE HP DNA Transfection Reagent to micro-
gram (!g) DNA has been shown to be optimal for many cell types.
 Lower cell confluencies have also been tested successfully.
The recommended starting concentration is a 3:1. For most cell types, 
these X-tremeGENE HP DNA Transfection Reagent to DNA ratios pro-
vide excellent transfection efficiency. 
 Further optimization may increase transfection efficiency in your 
particular application. In addition to varying the ratio, other param-
eters may also be evaluated, such as the amount of transfection 
complex added. For additional optimization guidelines, see Section 
3, Troubleshooting and visit  
http://www.powerful-transfection.com.
Plasmid DNA
• For best results, accurately determine the plasmid DNA concentra-
tion using 260-nm absorption; estimates of DNA by measuring gel 
band density are not recommended. Determine DNA purity using a 
260 nm/280 nm ratio (the optimal ratio is 1.8).
• Prepare the plasmid DNA solution using sterile TE (Tris/EDTA) buf-
fer or sterile water at a concentration of 0.1 to 2.0 µg/µl.
• Use high quality DNA preparation kits to obtain endotoxin-free 
DNA.
Cell Culture Conditions
• Minimize intra- and inter-experimental variance in transfection effi-
ciency using cells that are regularly passaged, proliferating well in a 
log-growth phase, and plated at a consistent density. 
• For best results, accurately quantify cell concentration using a 
hematocytometer or  automated system.
• Cells must be healthy and free of Mycoplasma.
• Cells should have a low passage number to achieve best results.
Other Media Additives 
In some cell types, antimicrobial agents (e.g., antibiotics and fungi-
cides) commonly included in cell-culture media may adversely affect 
the transfection efficiency of X-tremeGENE HP DNA Transfection 
Reagent. If possible, exclude additives in initial experiments. Once 
high-efficiency conditions have been established, these components 
can be added back while monitoring transfection results. Cell growth 
and/or transfection efficiency may be affected by variations in serum 
quality and medium formulations.
Verification of Vector Function
Optimize transfection conditions using a known positive-control 
reporter gene construct before transfecting cells with a new vector 
construct:
• Determine transfection efficiency using a reporter gene assay, such 
as "-Gal*, Luciferase*, or SEAP*.
• Sequence flanking vector insert regions to verify the integrity of 
your new construct.
2.2 Preparation of Cells for Transfection
Adherent Cells: Plate cells approximately 24 hours before transfec-
tion making sure cells are at the optimal concentration in the appropri-
ate cell culture vessel.
Suspension Cells: Plate freshly passaged cells at optimal concentra-
tion.
2.3  Transfection Procedure
! Allow X-tremeGENE HP DNA Transfection Reagent, DNA and 
diluent to equilibrate to +15 to +25°C. Briefly vortex the 
X-tremeGENE HP DNA Transfection Reagent vial.
" Dilute DNA with appropriate diluent (e.g., serum-free 
medium) to a final concentration of 1 µg plasmid DNA /100 µl 
medium (0.01 µg/µl). Mix gently.
# Place 100 µl of diluent, containing 1 µg DNA into each of four 
sterile tubes labeled 1:1, 2:1, 3:1, and 4:1.
 Use a minimum of 100 µl of diluent. Lower volumes may 
significantly decrease transfection efficiency.
 Use sterile tubes or tissue culture treated round-bottom, 
96-well plates to produce the complex.
$ Pipet the X-tremeGENE HP DNA Transfection Reagent (1, 2, 3, 
or 4 µl) directly into the medium containing the diluted DNA 
without coming into contact with the walls of the plastic tubes. 
Mix gently.
 To avoid adversely affecting transfection efficiency, do not 
allow undiluted X-tremeGENE HP DNA Transfection 
Reagent  to come into contact with plastic surfaces. Do not 
use siliconized pipette tips or tubes.
% Incubate the transfection reagent:DNA complex for 15 min-
utes at +15 to +25°C.
 Some ratios and cell types may required longer incubation 
(up to 30 min). Determine this for your particular cell line 
and the ratio used.
& Remove the culture vessel from the incubator. Removal of 
growth medium is not necessary. Add the transfection com-
plex to the cells in a dropwise manner. 
 See Table 1 to determine component amounts corre-
sponding to the surface area of the cell culture vessel 
used.
Gently shake or swirl the wells or flasks to ensure even distri-
bution over the entire plate surface. If available, use a rotating 
platform shaker for 30 seconds at low speed for mixing 
96-well plates.
Once the transfection reagent: DNA complex has been added 
to the cells, there is no need to replace with fresh medium (as 
may be necessary with other transfection reagents)
' Following transfection, incubate cells for 18 – 72 hours before 
measuring protein expression. The duration of incubation will 
depend on many factors, including the transfected vector con-
struct, the cell type being transfected, the cell medium, cell 
density, and the type of protein being expressed. After the 
incubation period, measure protein expression using an assay 
appropriate for your system.
Notes:
 As with any experiment, include appropriate controls. Prepare cul-
ture wells with cells that remain untransfected, cells with transfec-
tion reagent alone, and cells with DNA alone.
 For stable transfection experiments, the complex-containing 
medium should be left unchanged until the cells are passaged. At 
that time, include appropriate selection antibiotics (e.g., G 418 
Solution or Hygromycin B).
 To prepare transfection complexes for different-sized containers 
or parallel experiments,  adjust component amounts correspond-
ing to the surface area of the cell culture vessel used (see 
Table 1).
 For ease-of-use when transfecting small volumes into 96-well 
plates containing 0.1 ml culture medium per well, prepare 100 µl 
of transfection complex, and then add 10 µl to each well (depend-
ing on cell type).
 The optimal ratio of transfection reagent to DNA, and the optimal 
total amount of complex, will depend on the cell line, cell density, 
day of assay, and gene expressed.
 After performing the optimization experiment in which several dif-
ferent ratios are tested, select a ratio in the middle of the plateau 
optimum for future experiments.
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Tab. 1: Guidelines for Preparing X-tremeGENE HP DNA Transfection Reagent: DNA Complex for Various Culture Vessel Sizes
Culture vessel Surface Area 
(cm²)
Total volume of 
medium (ml)
Suggested 
amount of  
100 µl 
transfection 
complex 
to add to  
each well (µl)
DNA (µg)  
using 1:1  
or 4:1 Ratio 
Final amount  
of X-tremeGENE 
HP DNA 
Transfection 
Reagent (µl)  
using 1:1 Ratio
Final amount  
of X-tremeGENE 
HP DNA 
Transfection 
Reagent (µl) 
using 4:1 Ratio
96-well plate
(1 well)
0.3 0.1 10 0.1 0.1 0.4
48-well plate
(1 well)
1.0 0.3 30 0.3 0.3 1.2
24-well plate
(1 well)
1.9 0.5 50 0.5 0.5 2
12-well plate
(1 well)
3.8 1 100 1 1 4
35-mm dish 8 2 200 2 2 8
6-well plate
(1 well)
9.4 2 200 2 2 8
60-mm dish 21 5 500 5 5 20
10-cm dish 55 10 1000 10 10 40
T-25 flask 25 6 600 6 6 24
T-75 flask 75 20 2000 20 20 80
2.4 Troubleshooting
Observation Possible Cause Recommendation
Low Transfection 
Efficiency
Suboptimal X-tremeGENE HP DNA Transfec-
tion Reagent : DNA ratio
Titrate optimal X-tremeGENE HP DNA Transfection Reagent : DNA 
ratio. Refer to the text in Section 2.1 “Before you begin”.
Insufficient number of cells Determine optimal cell density for each cell type. For most cell types, 70 
– 90% confluence at transfection is optimal.
X-tremeGENE HP DNA Transfection Reagent : 
DNA complexes did not form well
Prepare complexes in serum-free medium (e.g., Opti-MEM).
Do not use siliconized pipet tips or tubes.
Do not aliquot the X-tremeGENE HP DNA Transfection Reagent.
Incubation time of transfection Determine the optimal incubation time (18 - 72 h). Optimal for most cell 
types and plasmids is 24 – 48h.
Inhibition by media components Some media components (e.g., polyanions) may influence the transfec-
tion.
Low volume of X-tremeGENE HP DNA Trans-
fection Reagent : DNA complex
The minimum amount of X-tremeGENE HP DNA Transfection Reagent 
to DNA complex is 100 µl. Complex formation at lower volumes may sig-
nificantly decrease the transfection efficiency; refer to the text in Section 
1, “Special Handling”.
High Cytotoxicity Cell density not optimal For each cell type, the optimal density should be determined. For most 
cell types, 70 - 90 % confluence at transfection is recommended, but 
other confluencies may increase cell viability.
Cells are cultured in serum-free medium Transfection using X-tremeGENE HP DNA Transfection Reagent in cells 
cultured in serum-free medium is possible, however, toxicity may be 
higher when serum is absent.
X-tremeGENE HP DNA Transfection Reagent : 
DNA complexes and cells not mixed well
Add X-tremeGENE HP DNA Transfection Reagent dropwise to the cells. 
Gently rock the dish/plate back and forth and from side to side to evenly 
distribute the complexes.
Plasmid preparation contaminated with endo-
toxin
Use highly purified, contaminant-free DNA for transfection.
Transfected protein is cytotoxic or is produced 
at high levels
Reduced viability or slow growth rates may be due to high levels of pro-
tein expression, with cellular metabolism directed toward production of 
the heterologous protein. Note that the expressed protein may also be 
cytotoxic at the expressed levels.
Too much transfection complex for number of 
cells
Increase the number of plated cells, and/or decrease the total amount of 
complex added to the cells.
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Protein Extraction Protocol 
1) Do all steps on ice or at 4o. 
 
2) Rinse cells with 1X PBS (1 ml, ice cold) 
 
3) Add 0.5 ml lysis buffer/well 
 
4) Incubate on ice for 20 min. 
 
5) Scrape into microfuge tube 
 
6) Transfer extract to Dounce homogenizer and homogenize with 10 strokes of 
Dounce homogenizer (tight pestle) 
 
7) Transfer extract back to microfuge tube 
 
8) Spin in microfuge in cold room for 10 min at max speed  
 
9) Transfer supernatant to new tube.  Save pellet. 
 
 
Igepal-DOC lysis buffer    
1% Igepal     
0.4% deoxycholate 
10mM Tris pH7. 
6.6mM EDTA 
 
-add 1X protease inhibitor cocktail before using lysis buffers 
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SDS polyacrylamide gel electrophoresis and Western Blot 
 
Materials 
BCA protein assay (Pierce Biotech, cat. #23225) 
Mini-PROTEAN II gel apparatus (Biorad) 
Costar gel-loading tips (Krackler Scientific, cat. #MN520R-LRS) 
Prestained SDS-Page broadrange molecular weight standard (NEB, cat. #P7708S) 
Trans-blot Semi-Dry Transfer cell (Biorad)        
Immobilon-P membrane (Millipore, cat. #IPV00010) 
heat-sealable bags (Kapak, cat. #TRS-95250) 
Kodak Biomax light autoradiagraphy film, 13 x 18 cm (Perkin Elmer Life Sciences, cat. 
#868-9358)  
Radtape (Diversified Biotech, cat. #RAD-10) 
 
Reagents 
TEMED (Sigma) 
Tween-20 (Sigma) 
Price Chopper non-fat dry milk 
Isopropanol (Sigma) 
 
Gel Buffers 
Acrylamide solution (30% acrylamide/0.8% bis-acrylamide) 
-dissolve 30g acrylamide (FW=71.08), 0.8g bis-acrylamide (FW=154.17) in a 
total volume of 100ml water. Filter through 0.2um filter. 
 
4X Running Gel Buffer (1.5M Tris, pH 8.8) 
-dissolve 36.3g Tris Base (FW=121.1) in 150ml water. Adjust to pH 8.8. Add 
water to total volume of 200ml. Filter through 0.2um filter.     
 
4X Stacking Gel Buffer (0.5M Tris, pH 6.8) 
-dissolve 12.1g Tris Base (FW=121.1) in 150ml water. Adjust to pH 6.8. Add 
water to total volume of 200ml. Filter through 0.2um filter. 
 
10% SDS 
 -dissolve 10g SDS (FW=288.38) in a total volume of 100ml water. 
 
10% Ammonium Persulfate 
 -dissolve 1.0g APS (FW=228.2) in a total volume of 10ml water. Store at -20˚C in 
50-100ul aliquots. 
 
1M Tris, pH 6.8 
-dissolve 12.1g Tris Base (FW=121.1) in 80ml water. Adjust to pH 6.8. Add 
water to total volume of 100ml. Filter through 0.2um filter. 
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6X SDS Sample Buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 
0.06% bromophenol blue) 
-combine 3.75ml 1M Tris-Cl, pH 6.8, 6ml glycerol, 1.2g SDS (FW=288.38), 0.93g 
DTT (FW=154.2), 6mg bromophenol blue. Add water to total volume of 10ml. 
Store at -20˚C in 0.5ml aliquots. 
2X SDS Sample Buffer (0.125M Tris pH 6.8, 4% SDS, 20% glycerol, 0.2M DTT, 
0.02% bromophenol blue) 
-combine 2.5ml 4X Tris pH 6.8 (stacking gel buffer), 2ml glycerol, 4ml 10% SDS 
(FW=288.38), 0.31g DTT (FW=154.2), 2mg bromophenol blue. Add water to total 
volume of 10ml. Store at -20˚C in 0.5ml aliquots. 
1X SDS Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.1M DTT, 
0.01% bromophenol blue) 
 
5X Electrophoresis Buffer (0.125M Tris, 0.96M glycine, 0.5% SDS) 
-dissolve 30.3g Tris Base (FW=121.1), 144.1g glycine (FW=75.07), and 10g SDS 
(FW=288.38) in a total volume of 2L water.                                                   
1X Electrophoresis Buffer (0.025M Tris, 0.192M glycine, 0.1% SDS) 
 -add 200ml 5X electrophoresis buffer to 800ml water. 
 
Western Blot Buffers 
Transfer Buffer (0.048M Tris, 0.039M glycine, 20% methanol, 0.00375% SDS)     
-dissolve 11.64g Tris Base (FW=121.1), 5.86g glycine (FW=75.07) in ~1500ml 
water. Add 0.750ml 10% SDS (FW=288.38). Add 400ml methanol. Add water to 
total volume of 2L. No pH adjustment necessary. 
 
10X TBST Wash Buffer (0.1M Tris HCl, 1.5M NaCl, 0.5% Tween-20)         
-dissolve 31.52g Tris HCl (FW=157.6), 175.32g NaCl (FW=58.44) in ~1900ml 
water. Add 10ml       Tween-20. Adjust to pH 7.2.  Add water to total volume of 
2L.     
 
1X TBST Wash Buffer (0.01M Tris HCl, 0.15M NaCl, 0.05% Tween-20) 
 -add 100ml 10X TBST to 900ml water. 
 
5% milk Blocking Buffer  
-Dissolve 5g milk in a total volume of 100ml 1X TBST.   
 
Method    
1. Determine cell number or protein concentration to be loaded onto gels and what 
volume to load per well.  Note max volumes for different comb configurations.  
 
2. Usually add sample to Tris or PBS and then add sample buffer (2 ul sample + 18 ul 
PBS + 3.3 ul 6X sample buffer).  
 
3. Sonicate cells briefly on ice to homogenize.  Purified protein samples do not need to be 
sonicated.  
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4. Preparing resolving and stacking gels (for BioRad Mini-PROTEAN II): Make sure 
glass plates are clean.  Use Sparkleen or Alconox powder to clean plates.  Rinse with 
distilled water and then 95% EtOH.  Wipe dry with KimWipes.  Select a comb and spacer 
(ex. 0.75 mm).  Place spacers in between the inner and outer glass plates.  Make sure that 
the spacers are flush with the plates. Insert plates into the clamping assembly and tighten 
screws.  Vacuum grease can be used on the casting stand gaskets to prevent buffer 
leakage.  Snap assembly into the casting stand.  Prepare resolving gel.  Pour gel and 
overlay with 1X Electrophoresis Buffer or isopropanol (use 3.5ml resolving gel when 
using 0.75mm spacers and 7.0ml gel for 1.5mm spacers, this will produce a gel approx. 
3.25" x 2"). Look for a division between the overlay and resolving gel, this means the gel 
is polymerized.  Pour off overlay, use thin strips of Whatman paper to remove any 
excess.  Pour stacking gel and insert comb.  Remove comb when stacking gel is 
polymerized.  Use a syringe and a 12 gauge needle to wash stacking gel wells. Snap 
clamp assembly into electrode assembly.  Vacuum grease can be used on electrode 
assembly gaskets to prevent buffer leakage. 
 
5. Boil samples 5 minutes at 100°C, and then spin tubes at 13,000rpm for ~1min. in RT 
micro centrifuge. Load samples using Costar Gel-Loading Tips.     
 
6. Place electrode assembly with loaded samples into an electrophoresis chamber. Fill the 
electrode assembly carefully with 1X Electrophoresis Buffer. Fill the electrophoresis 
chamber with 1X Electrophoresis Buffer.  Run gels at 100V for stacking gel, 100-150V 
for resolving gel (can increase to 200V for resolving gel if running on ice). 
   
7. To transfer mini- gels to Immobilon-P membrane using the BioRad Semi-Dry Transfer 
Cell:  Remove gels from glass plates. Cut stacking gel away and discard. Incubate gels in 
Transfer Buffer for 20 - 40 min. Cut out 6 pieces of Whatman paper and 1 piece of 
Immobilon-P membrane for each gel that is being transferred. They should be 3.25" x 2". 
Incubate Immobilon-P membrane in Methanol for ~10 - 20 seconds. Wet Immobilon-P 
membrane and Whatman paper in Transfer Buffer for 5 - 10 minutes before assembling 
the gel sandwich according to the BioRad Reference Guide. Transfer 1 mini-gel for 15 
min. at 15 V, max current.  Transfer 2 mini-gels for 30 min at 15 V, max current. Make 
sure that pre-stained MW markers transfer to Immobilon-P membrane.   
 
8. Western Blot:   
-Block membrane in 20ml blocking buffer overnight at 4°C or 1h at room 
temperature on rocker in a seal-a-meal bag. 
-Dilute Ab in blocking buffer (1:1000 for serum or 5ug / 10ml for purified Ab). 
Incubate blots with Ab for 1h at rom temperature or overnight at 4°C on rocker in 
a seal-a-meal bag. 
 -Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each. 
-Dilute HRP conjugated Ab 1:10,000. Incubate blots with secondary Ab for 1h at 
room temperature or overnight at 4°C on rocker in a seal-a-meal bag.                               
-Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each.     
-Add 5ml chemiluminescent substrate to each blot, incubate for 5 minutes. Place 
blots in between transparency film. Push out air bubbles. Develop Western blot. 
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Do a 1 minute exposure to check signal intensity. Continue with longer or shorter 
exposures as needed.   
               (Max. exposure length = 60 min.  Min exposure length = 1 sec.)  
 -For high backgrounds, wash in TBST then re-develop.    
 
Resolving Gel 
 
Running Gel: 7.5, 10, or 15% acrylamide, 0.375M Tris-Cl pH 8.8, 0.1% SDS, 0.33% 
APS, 0.66% TEMED 
 
                                                             Stacking Gel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stacking Gel: 4% acrylamide, 0.125M Tris-Cl pH 6.8, 0.1% SDS, 0.05%APS, 0.2% 
TEMED 
 
 
 7.5% gel (15ml) 10% gel (15ml) 
15% gel 
(15ml) 
Water 7.5ml 6.25ml 3.75ml 
30% 
acrylamide/ 
0.8% bis-
acrylamide 
3.75ml 5ml 7.5ml 
4X Running 
Buffer 3.75ml 3.75ml 3.75ml 
10% SDS 150ul 150ul 150ul 
10% APS 50ul 100ul 50ul 
TEMED 10ul 20ul 10ul 
 4% gel (10ml) 
Water 6.1ml 
30% acrylamide/ 
0.8% bis-acrylamide 1.3ml 
4X Stacking Buffer 2.5ml 
10% SDS 100ul 
10% APS 100ul 
TEMED 40ul 
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Protocol for non-permeabilizing IHC. 
1. Wash cells with 0.5ml 1X PBS 
2. Fix cells for 10 minutes at RT with 0.5ml 4% paraformaldehyde in 1X PBS 
3. Aspirate PFA and add 0.5ml 10mg/ml Glycine in 1X PBS for 10 minutes 
4. Block cells for 20 minutes with 0.5ml 5% BSA in 1X PBS 
5. Wash with 0.5ml 1X PBS. 
6. Incubate with primary antibody for 60 minutes. Antibody concentration is 1.0 
µg/ml in 0.5ml PBS with 5% BSA. 
7. Wash with three 0.5ml changes of PBS for 5 minutes each. 
8. Incubate for 45 minutes with secondary antibody diluted to 1µg/ml in 0.5ml PBS 
with 5% BSA. 
9. Wash with three 0.5ml changes of PBS. 
10. Mount coverslip with Vectashield or 90% glycerol in PBS with n-propyl galate 
(about 10ml). 
11. Store slides in a dark location at 4° C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	
